Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive
 T-cells by Selvan, R S et al.
Mucin (MUC-1) was initially identified with DU-PAN-2 murine
monoclonal antibody raised against a pancreatic adenocarcinoma
cell line, HPAF (Lan et al, 1985). Mucin detected on the surface of
established pancreatic tumour cells was also abundantly expressed
on tumour tissues (Borowitz et al, 1984). MUC-1 has also been
shown to be recognized by T-cells in vitro. Barnd et al (1989)
demonstrated that heterologous cytotoxic T-cells (CTLs) gener-
ated from lymph node cells of a patient recognized tumour-associ-
ated mucin in a specific, major histocombatibility complex
(MHC)-unrestricted fashion. Since a pancreatic tumour cell-
reactive autologous T-cell system was not available, heterologous
pancreatic tumour cell lines were used as stimulators of lymph
node cells (Barnd et al, 1989). MHC-unrestricted CTLs generated
against heterologous, mucin-expressing pancreatic tumour cells
were also reported to lyse breast tumour cells which expressed
MUC-1 (Barnd et al, 1989; Jerome et al, 1991). It was postulated
that tandem repeats and aberrant glycosylation of tumour cell
mucin were responsible for such a MHC-unrestricted recognition
by heterologous T-cells (Barnd et al, 1989; Jerome et al, 1991;
Poland et al, 1997). Recently, Margarian-Blander et al (1998)
demonstrated that direct recognition of the MUC-1 peptide epitope
by the T-cell receptor (TCR) in the absence of presentation by the
MHC induced a partial signal. However, mucin has yet to be
demonstrated as an antigen recognized by pancreatic tumour cell-
reactive, autologous T-cells. In this study, we investigated whether
pancreatic tumour-associated mucin is recognized by pancreatic
tumour-patients’ T-cells in a MHC-unrestricted fashion using
human leucocyte antigen (HLA)-defined heterologous and autolo-
gous systems, and whether purified mucin could elicit tumour-
reactive T-cells. Our study does not support the claim that
mucinous pancreatic tumour cell-reactive T-cells recognize mucin
in MHC-unrestricted fashion.
MATERIALS AND METHODS
Tumour cell lines
Previously established pancreatic adenocarcinoma cell lines
HPAF, CAPAN-1, CAPAN-2, T3M4, COLO-357 and PANC-1,
melanoma cell line SKMEL-14, breast carcinoma cell line SKBR-
3 were cultured in complete minimal essential medium (MEM),
containing with 100 U ml–1 penicillin, 100 mg ml–1 streptomycin,
2m M glutamine, and 10% heat-inactivated fetal bovine serum
(FBS; Barnd et al, 1989; Wahab and Metzgar, 1991). Myelogenous
leukemia cell line K-562 (obtained from Dr Zeinab Wahab, Duke
University) was cultured in complete RPMI-1640 medium. The
adherent tumour cell cultures were transferred regularly by
trypsinization (0.25% trypsin with 0.2% EDTA). Tissue culture
reagents were obtained from Gibco-BRL (Grand Island, NY,
USA). Cell lines were found to contain no mycoplasm determined
by enzyme-linked immunosorbent assay (ELISA) kit obtained
from Boehringer Mannheim (Indianapolis, IN, USA).
Establishment of primary pancreatic tumour cell line
WM-tumour explant cultures were established from a moderately
differentiated primary pancreatic tumour mass of a patient who
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et al, 1986). Briefly, a tissue sample was washed and teased in a
tissue culture dish (Falcon, Becton Dickinson, Franklin Lakes, NJ,
USA) in a medium consisting of 50% (v/v) Dulbecco’s modified
Eagle’s medium (DMEM), 50% (v/v) F-12 Ham medium supple-
mented with 10% FBS, 5 mg ml–1 insulin, 5 mg ml–1 transferrin and
5 ng ml–1 selenium, 100 U ml–1 penicillin and 100 mg ml–1 strepto-
mycin, 2 mM glutamine and 5 ´ 10–5 M 2-mercaptoethanol. Small
tissue fragments and freed cells were separated from the large
fragments and transferred into a 50 ml centrifuge tube (Corning
Inc., Corning, NY, USA). Large fragments (mostly connective
tissues) remaining in tissue culture dish were discarded. The
suspension containing small tissue fragments and freed cells was
allowed to stand at room temperature for 5 min. After the small
tissue fragments had settled, the cell suspension was transferred 
to another 50 ml centrifuge tube. The remaining small tissue 
fragments and freed cells were washed once by subjecting to
centrifugation at 1000 rpm for 10 min. Both preparations were
resuspended in complete DMEM/F-12 Ham medium and placed in
25-cm2 tissue culture flasks (Costar, Cambridge, MA, USA) at
37°C in humidified atmosphere containing 5% carbon dioxide.
Within 2–3 weeks, islands of epithelial cells were allowed to grow
by preventing the outgrowth of fibroblasts using differential
trypsinization procedure with low trypsin (0.05% trypsin and
0.02% EDTA; Gibco-BRL). By periodically repeating this proce-
dure, primary pancreatic tumour cell line, WM, was established.
Flow cytometry and immunocytochemistry of tumour
cells
The cultured WM and HPAF tumour cells were first trypsinized
and immediately resuspended in FBS containing medium. After
being washed twice, cells were resuspended in complete medium
and allowed to recover antigens by incubation at room tempera-
ture for 1–2 h. The expression of MHC-class I and -class II mole-
cules on the surface of tumour cells was determined using
indirect immunofluoresence assay essentially as described by us
(Selvan et al, 1991). The tumour cells were stained with anti-
HLA class I (W6/32) and anti-HLA class II (L243) antibodies
(affinity purified antibodies from tissue culture supernatant of
hybridomas were obtained from ATCC, Rockville, MD, USA)
respectively. The control cells were stained with isotype-
matched antibody (IgG2a; Sigma, St Louis, MO, USA). All
samples were stained with fluorescein-conjugated goat anti-
mouse antibodies (Organon Teknika, Durham, NC, USA) and
analysed for fluorescence intensity in an Ortho Cytofluorograph
50-H (Ortho Instruments, Westwood, MA, USA). The tumour
cells were further assessed for the expression of mucin using
immunocytochemical procedure as described elsewhere
(Borowitz et al, 1984). Briefly, tumour cells were grown to
confluence in multi-chamber culture slides (Lab-Tek, NUNC,
Inc., Laperville, IL, USA). Cells were washed with phosphate-
buffered saline (PBS) and fixed with cold acetone (–20°C). The
fixed cells were blocked with PBS containing 1% bovine serum
albumin (BSA; Sigma) and incubated with primary antibody
DU-PAN-2 (IgM; hybridoma culture supernatant was a gift from
Dr Zeinab Wahab, Duke University) or SP-1 supernatant. After
washing, the cells were incubated with goat anti-mouse IgG
peroxidase-conjugated antibody. The cells were washed in PBS,
stained with diaminobenzidine and counter stained with Gill’s
haematoxylin.
Immortalization of B-cells
Peripheral blood B lymphocytes from pancreatic tumour patients
were immortalized with tissue culture fluid containing
Epstein–Barr virus (EBV) from the marmoset cell line B95-8
essentially as described elsewhere (Miller and Lipman, 1973).
Briefly, 5 ´ 106 peripheral blood lymphocytes (PBLs) were
infected with EBV in the presence of 20 mg ml–1 cyclosporine and
cultured in RPMI-1640 medium containing 10% FBS for 4–6
weeks during which time the immortalized B-cells exhibited
active growth.
HLA typing 
HLA typing of tumour cells and PBLs was carried out using
complement-dependent microcytotoxicity assay with anti-HLA
monoclonal and polyclonal antibodies (Pollack et al, 1981).
Tumour-specific T-cell lines
Tumour cell-specific heterologous T-cell lines derived from
draining lymph nodes of pancreatic adenocarcinoma patients, were
established by stimulation with irradiated (6000 rad) heterologous
pancreatic tumour cells (HPAF, T3M4 and PANC-1) and 5 U ml–1
human recombinant interleukin-2 (IL-2; DuPont, Wilmington, DE,
USA) basically as described by Barnd et al (1989). Tumour-infil-
trating lymphocytes (TILs), and tumour cell-reactive autologous
T-cells from peripheral blood mononuclear cells (PBMCs) were
established with irradiated autologous tumour cells WM and IL-2
as described by us and others (Slovin et al, 1986; Belldegrun et al,
1989; Selvan et al, 1991). Leucocyte lineage-specific antigens on
the tumour-specific T-cells were determined using immunofluo-
rescence followed by cytofluorometric analysis using anti-CD3,
anti-CD4, anti-CD8, anti-CD19, anti-CD20, anti-CD16 and CD56
antibodies (tissue culture supernatants of hybridomas obtained
from ATCC).
Lymphokine-activated killer (LAK) cells
Effector lymphokine-activated killer cells were generated by
culturing PBMCs from mucinous pancreatic adenocarcinoma
patients with 1000 U ml–1 of IL-2 for 5 days (Grimm et al, 1982).
Culturing of T cells with purified mucin
Purified mucin used in this investigation was provided by Dr MS
Lan, a coinvestigator of the report by Barnd et al (1989) and the lot
of mucin preparation is the same as that used by Barnd et al (1989)
(M Lan, personal communication). Mucin was prepared as
described elsewhere (Lan et al, 1985, 1987). The quantity and
purity of mucin preparations were qualified by the levels of reac-
tivity against DU-PAN-2 antibody using competitive inhibition
radioimmunoassay (RIA; Metzgar et al, 1984) and Western blot
analysis respectively (Lan et al, 1985, 1987). Rather than express
the results as percent inhibition and titre, the quantity of DU-PAN-
2 antigen in a sample was expressed as arbitrary units ml–1 based
on reference to the partially purified standard antigen sample. The
amount of DU-PAN-2 antigen in 20 ml of a 1:500 dilution of the
standard antigen preparation was designated as 100 units ml–1
(Metzgar et al, 1984). The heterogeneity of mucin antigen migra-
tion on the gel indicated that the monoclonal antibody DU-PAN-2
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(Lan et al, 1985, 1987). The buoyant densities and amino acid
compositions of purified fractions (I and II) suggested that DU-
PAN-2 antibody-reacting antigen was mucin-like glycoprotein
(Lan et al, 1987). IL-2 used in our experiments was obtained from
Dupont (Wilmington, DE, USA) which is the same as used by
Barnd et al (1989). One times 106 heterologous tumour-specific T-
cell lines per ml (from lymph node cells of a mucinous pancreatic
adenocarcinoma patient, established against mucinous T3M4 or
non-mucinous PANC-1 pancreatic tumour cell lines) were repeat-
edly cultured with 1900 U ml–1 mucin and 5 U ml–1 IL-2 in 24-well
flat-bottomed tissue culture plates (Costar, Costar Corp.,
Cambridge, MA, USA). Similarly, freshly isolated PBMCs from
pancreatic adenocarcinoma patients were cultured with mucin plus
IL-2. The leucocyte cultures were periodically cleared off excess
debris by centrifugation through Ficoll gradient (Organon
Technica). The cultures were repeatedly restimulated with mucin
after a cycle of culturing with mucin plus IL-2 for 3–4 days
followed by IL-2 alone for 2–3 days. Some of the cultured cells
were tested in triplicates for their ability to lyse T3M4, HPAF,
PANC-1 and natural killer (NK) cell target K-562 or to proliferate
against purified mucin. To determine the proliferation, 105 PBMCs
from cancer patients were incubated in triplicates with 5 U ml–1 IL-
2 or varying concentrations (475 U ml–1 to 2375 U ml–1) of mucin
in the presence or absence of 5 U ml–1 IL-2 in 96-well flat-
bottomed tissue culture plates (Costar). After 72 h, the wells were
pulsed with 1 mCi per well [3H]thymidine and incorporation of
[3H]thymidine into DNA of proliferating cells was measured as
described below.
Cytolytic assay
The cytolytic activity of tumour-infiltrating lymphocytes, periph-
eral blood tumour-specific T-cells, LAK cells and mucin-stimu-
lated T-cells or PBMCs was assayed using 4 h Chromium-51
release assay (Barnd et al, 1989; Selvan et al, 1990, 1991). As
targets, we used several well established tumour cell lines
including the heterologous pancreatic cancer cell lines HPAF,
T3M4, PANC-1, COLO-357, CAPAN-1 and CAPAN-2, the autol-
ogous pancreatic cancer cell line WM and EBV-immortalized B
cells, the breast tumour cell line SKBR-3, the melanoma cell line
SKMEL-14 and the myelogenous leukaemia cell line K-562
(Barnd et al, 1989). In some cases, target cells were preincubated
with 20 mg ml–1 control antibody (IgG2a; Sigma) or anti-MHC class
I antibody (W6/32) to block MHC class I-mediated cytolytic
response. These target cells were then washed three times in RPMI
medium and the cytotoxicity assay in triplicate samples was
performed at various effector to target ratios as described above.
Proliferation assay
The proliferative rate was determined in triplicate samples for
isolated tumour-infiltrating T-cells and peripheral blood tumour-
reactive T-cells (Barnd et al, 1989; Selvan et al, 1990, 1991).
Briefly, 105 responder resting T-cells were incubated with 104 irra-
diated autologous or heterologous stimulator cells for 3 days at
37°C in complete medium supplemented with 10% FBS in the
presence or absence of 1 U ml–1 IL-2. The cells were then pulse-
labelled with 1 mCi per well of [3H]thymidine for the last 18 h at
37°C and harvested using a Skatron cell harvester (Skatron
Instruments Inc., Sterling, VA, USA). The incorporation of
[3H]thymidine was quantitated using a liquid scintillation counter
(Wallac 1409, Wallac Oy, Turku, Finland). In some cases, irradi-
ated stimulator cells were preincubated with 20 mg ml–1 control
antibody (IgG2a; Sigma) or anti-MHC class II antibody (L243) to
block MHC class II-mediated proliferative response. In other
cases, 10 mg ml–1 affinity purified antibody against pancreatic
tumour mucin, DU-PAN-2 or SP-1 supernatant was included
(Barnd et al, 1989). These cells were then washed three times in
RPMI medium and added at proper concentration to the responder
T-cells. The proliferative response of T-cells was measured as
described above.
Statistical analysis
All determinations were made in triplicate and data are reported as
the mean ± s.e.m. The statistical analysis of data was carried out
using Student’s t-test, and P < 0.05 between two groups were
considered to be statistically significant.
RESULTS
Heterologous pancreatic tumour-reactive cytotoxic
T-cells do not recognize pancreatic tumour cells in
the context of MHC-unrestricted mucin
In an effort to determine whether heterologous cytotoxic T cells
recognize mucin expressed by human pancreatic tumour cells,
cytotoxic T-cell lines (TP and RM) were established from draining
lymph nodes of pancreatic tumour patients by stimulating with
mucin-expressing (T3M4 or HPAF) and non-mucin-expressing
(PANC-1) tumour cells (Table 1). The tumour patients had very
high levels of mucin in the serum at the time of surgery, deter-
mined by enzyme-linked immunosorbent assay (ELISA) using
DU-PAN-2 monoclonal antibody (Metzgar et al, 1984; data not
shown). Cytotoxic T-cells derived from draining lymph node cells
of a pancreatic adenocarcinoma patient (TP) were generated
against heterologous, mucin-expressing pancreatic tumour cell
line T3M4 in the presence of 5 U ml–1 IL-2. The established cyto-
toxic T-cells effectively lysed the stimulator cells, T3M4 (78%
lysis at effector:target ratio of 25:1) as well as another target
(CAPAN-1) that expressed mucin (87% lysis). The same effector
cells, however, did not lyse other mucin-expressing pancreatic
tumour cell lines such as HPAF or COLO-357 but exhibited a 
low level reactivity (20–23% lysis) towards mucin-expressing
CAPAN-2 cells as well as non-mucin-expressing PANC-1 cells. In
a similar fashion, TP cytotoxic T-cells established against mucin-
expressing HPAF cells effectively lysed the HPAF cells (71%
lysis). These cytotoxic T-cells elicited a range of low level reac-
tivity (19–28% lysis) towards mucin-expressing CAPAN-1 and
T3M4 cells, and non-mucin-expressing PANC-1 cells. TP cyto-
toxic T-cells established against non-mucin-expressing PANC-1
cells very effectively lysed PANC-1 cells (78% lysis) and
melanoma cell line SKMEL-14 (76% lysis) and, at a low level
(23% lysis) mucin-expressing T3M4 cells but not other mucin-
expressing pancreatic tumour cells. A similar reactivity was also
seen with RM cytotoxic cells established from pancreatic adeno-
carcinoma patient against T3M4, HPAF or PANC-1 cells (Table
1). Interestingly, none of the heterologous T-cells established
against mucin-expressing pancreatic tumour cells were able to lyse
mucin-expressing breast tumour cell line SKBR-3. Previous
studies from elsewhere have shown that heterologous, pancreatic
T-cells lack atypical recognition of mucin 693
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Table 1 Tumour target cell lysis by heterologous pancreatic tumour-reactive T-cellsa
% Specific lysis by cytotoxic T-cells
established against heterologous tumour cellsb
Responder Targets
T-cells tested T3M4 HPAF PANC-1
TP Pancreatic adenocarcinoma
CAPAN-1 86.88 ± 1.57 21.46 ± 1.00 1.11 ± 0.61
CAPAN-2 22.75 ± 1.19 –3.71 ± 0.31 2.44 ± 0.57
T3M4 78.17 ± 0.08 27.93 ± 0.75 23.37 ± 0.31
HPAF 2.30 ± 0.57 70.60 ± 0.58 2.83 ± 0.14
COLO-357 1.87 ± 0.62 4.71 ± 0.28 2.52 ± 0.99
PANC-1 (non-mucinous) 20.43 ± 0.91 18.60 ± 0.51 78.20 ± 0.86
Melanoma
SKMEL-14 11.20 ± 0.35 9.02 ± 0.28 75.70 ± 0.80
Myelogenous leukaemia
K-562 4.91 ± 0.84 4.94 ± 0.56 2.99 ± 0.73
RM Pancreatic adenocarcinoma
CAPAN-1 65.02 ± 1.85 26.19 ± 2.17 7.81 ± 0.42
CAPAN-2 35.86 ± 2.09 24.91 ± 2.64 1.31 ± 0.83
T3M4 73.00 ± 3.45 28.25 ± 1.04 11.99 ± 0.84
HPAF NT 33.05 ± 1.47 NT
COLO-357 29.31 ± 0.86 –5.83 ± 2.30 3.50 ± 1.26
PANC-1 (non-mucinous) 22.51 ± 0.71 38.59 ± 2.69 61.84 ± 2.95
Melanoma:
SKMEL-14 1.97 ± 0.28 9.17 ± 0.26 22.17 ± 0.57
Breast carcinoma:
SKBR-3 –0.25 ± 0.41 1.38 ± 0.93 –0.31 ± 0.64
Myelogenous leukaemia
K-562 11.60 ± 0.28 NT 9.51 ± 1.06
aCytotoxic T-cells TP and RM were established from tumour-draining lymph nodes of pancreatic adenocarcinoma patients against heterologous pancreatic
tumour cells T3M4, HPAF or PANC-1 by repeated stimulation with irradiated tumour cells in the presence of 5 U ml–1 interleukin-2. The data represent the
cytolytic activity of T-cell lines assessed at about 2 months of continuous culture against Chromium-51-labelled tumour cell targets using various effector
(E) to target (T) ratios. bValues represent percentage specific lysis obtained at E:T 25:1 in a 4 h Chromium-51 release assay. NT, not tested.
Table 2 Heterologous pancreatic tumour-reactive cytotoxic T cells do not recognize pancreatic tumour cells in the context of MHC-unrestricted mucin
HLA-typing of HLA-typing of
effector cells target cells
Effector (Class I) Target (Class I) % Cytotoxicityd
1. RC-T cell A3,A30; B18,B27; WM A1*, A3#; B7,B37; 35.21 ± 1.79
line against Bw4,Bw6 Bw4,Bw6; Cw6
WM-tumour HPAF A1,A34; B8,B22; 55.58 ± 1.03
cellsa Bw6; Cw3
K-562 HLA Class I-negative 0.01 ± 0.80
(NK Cell Target)
2. WM-T cell A1,A3; B7,B37; HPAF A1,A34; B8,B22; 39.83 ± 1.71
line against Bw4,Bw6; Cw6 Bw6; Cw3
HPAF-tumour WM A1,A3; B7,B37; 1.27 ± 0.53
cellsb Bw4,Bw6; Cw6
FW-PBL A1; B8; Bw6; Cw7 61.27 ± 1.61
Blastsc (homozygous)
K-562 HLA Class I-negative –1.61 ± 0.64
(NK Cell Target)
aRC- and bWM-cytolytic effector T-cell lines were established from peripheral blood mononuclear cells of pancreatic adenocarcinoma patients against
heterologous, mucin-expressing pancreatic tumour cells, WM and HPAF respectively, in the presence of 5 U ml–1 interleukin-2. cFW-peripheral blood cells were
stimulated with PHA (2 mg ml–1) for 48 h and the resultant blast cells were labelled with Chromium-51 and used as target cells. dCytolytic activity of T-cells
against indicated tumour targets were assayed at about 3 months after continuous culture using various effector (E) to target (T) ratios. The values represent
percentage specific lysis obtained at E:T 25:1 in a 4 h Chromium-51 release assay. The results shown are representative of five experiments. *Bold face
denotes shared-MHC class I alleles on target cells recognized by effector cytotoxic T-cells. #Underlining denotes matched-MHC class I alleles between
responder and stimulator or target cells.tumour cell-reactive T-cells also recognized breast tumour cells
due to the expression of similar mucin (Barnd et al, 1989; Jerome
et al, 1991). The present results show that cytotoxic T-cells derived
from patients with mucin-expressing pancreatic adenocarcinoma
exhibit reactivity in a typical fashion by effectively lysing predom-
inantly the cells that were used as stimulators. A cytolytic response
seen against few other targets in this study suggests that these
target cells have HLA-alleles matched with the stimulators.
To more precisely understand the reactivity of heterologous
cytotoxic T-cells towards mucin-expressing pancreatic tumour
cells, a set of HLA-defined tumour patient cytotoxic T-cells were
established by stimulation with HLA-defined heterologous,
mucin-expressing pancreatic cancer cells in the presence of IL-2.
As shown in Table 2, cytotoxic T-cell responses against heterolo-
gous, mucin-expressing pancreatic tumour cell targets occurred
primarily as a typical allogeneic response. RC cytotoxic T-cells
lysed the heterologous target tumour cells, WM, that were used as
stimulators (35% lysis at E:T 25:1) as well as the target HPAF cells
that had a matching MHC class I allele (A1) (56% lysis at E:T
25:1). In a similar fashion, WM cytotoxic T-cells established
against HPAF cells, lysed HPAF cells (40% lysis at E:T 25:1) as
well as non-mucinous target PBL-blast cells (61% lysis at E:T
25:1) that had a MHC-class I allele (B8) matched to HPAF cells.
These CTLs (WM), however, did not lyse autologous tumour cells
in spite of expressing mucin on their surface. Preincubation of
target cells with W6/32 antibody blocked the cytotoxicity
(83–86% inhibition) of both RC as well as WM CTLs irrespective
of whether target cells expressed mucin (Table 3). The results
demonstrate that heterologous T-cells generated against mucin-
expressing pancreatic tumour cells appear to lyse targets, not in the
context of mucin but in a typical alloreaction.
Autologous pancreatic tumour-reactive T-cells do not
recognize mucin on tumour cells in MHC-unrestricted
fashion
To circumvent the response of heterologous T-cells to disparate
MHC molecules on heterologous pancreatic tumour cells, an
autologous pancreatic tumour cell-reactive T-cell system (WM)
was established from a surgically excised primary pancreatic
adenocarcinoma. The system comprised of a tumour cell line,
tumour cell-reactive T-cell lines from TILs and peripheral blood
lymphocytes, and EBV-transformed B-cells. Characterization of
the tumour cell line revealed that tumour cells expressed mucin as
determined by immunoperoxidase staining with DU-PAN-2 anti-
body (Figure 1) (Borowitz et al, 1984), and that the tumour cell
line was MHC class I as well as class II-positive (Figure 2). Both
TILs and tumour cell-reactive T-cells from peripheral blood prolif-
erated against autologous tumour cells, WM, but not against
heterologous pancreatic tumour cells, HPAF (Table 4), and were
shown to be CD4+ T-cells (data not shown). These cells exhibited
no cytolytic function against the autologous tumour cells, WM
(data not shown). Since the TIL line was established in the pres-
T-cells lack atypical recognition of mucin 695
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Table 3 Anti-MHC class I antibody inhibits heterologous, pancreatic tumour-
reactive CTL killing of mucin-expressing and -non-expressing target cells
Effector Target %
Cytotoxicityd
1. RC-T cell WM + Control antibody 37.83 ± 0.80
line against WM + W6/32 antibody 5.33 ± 0.48 (86%)
WM-tumour HPAF + Control antibody 49.23 ± 2.91
cellsa HPAF + W6/32 antibody 8.14 ± 1.83 (83%)
2. WM-T cell HPAF + Control antibody 42.45 ± 1.00
line against HPAF + W6/32 antibody 7.32 ± 1.63 (83%)
HPAF-tumour WM + Control antibody 1.37 ± 0.50
cellsb WM + W6/32 antibody 1.41 ± 0.55
FW-PBL Blastsc + Control antibody 57.23 ± 2.69
FW-PBL Blasts + W6/32 antibody 9.44 ± 1.37 (84%)
aRC- and bWM-cytolytic effector T-cell lines were established from peripheral
blood mononuclear cells of pancreatic adenocarcinoma patients against
heterologous, mucin-expressing pancreatic tumour cells, WM and HPAF
respectively, in the presence of 5 U ml–1 interleukin-2. cFW-peripheral blood
cells were stimulated with PHA (2 mg ml–1) for 48 h and the resultant blast
cells were labelled with Chromium-51 and used as target cells. dCytolytic
activity of T-cells against indicated tumour targets preincubated (60 min at
37°C) with 20 mg ml–1 control antibody (IgG2a) or W6/32 antibody and washed
in RPMI medium, were used in cytotoxic assay employing various effector (E)
to target (T) ratios. The values represent percentage specific lysis obtained at
E:T 25:1 in a 4 h Chromium-51 release assay. HLA pattern of effector and
target cells are given in Table 2. Similar results were obtained in another
experiment. The values in parentheses represent percent inhibition of
cytotoxicity over respective controls.
A
B
Figure 1 Expression of mucin on WM-pancreatic tumour cells. Cultured
WM cells grown to confluence on a multichamber slide (NUNC) were stained
with (A) control antibody (SP-1 supernatant), and (B) anti-mucin IgM
antibody (DU-PAN-2) followed by peroxidase-conjugated goat anti-mouse
antibody and developed with the substrate diaminobenzidine (Borowitz et al,
1984). Immunostained cells were counter stained with Gill’s haematoxylinence of IL-2, these cells expressed a proliferative response to IL-2
alone. When irradiated autologous tumour cells were added with
IL-2, a tumour-specific proliferative response was consistently
observed (P < 0.05). Such a proliferative response of these T-cells
could not be detected against heterologous, mucin-expressing
pancreatic tumour cells, HPAF (Table 4), or autologous EBV-
immortalized B-cells (Table 5). In addition, inclusion of anti-MHC
class II antibody (L243) but not anti-mucin antibody (DU-PAN-2)
inhibited the proliferative response of TILs against autologous
mucin-expressing pancreatic tumour cells, WM (P < 0.05; Table
5). Autologous tumour-specific T-cell lines established from PBLs
of the same patient elicited a significant response similar to
tumour-infiltrating lymphocytes (P < 0.01; Table 4). The results do
not support the contention that MHC-unrestricted mucin is
involved in the patients’ T cell-recognition of pancreatic tumour
cells.
Lymphokine-activated killer cells do not recognize
pancreatic tumour cells in the context of mucin
We investigated whether HLA-defined autologous, and heterolo-
gous, lymphokine-activated killer cells (WM- and RC-LAK cells
respectively) recognize pancreatic tumour-associated mucin
(Table 6). LAK cells, derived from PBMCs, lysed heterologous,
mucin-expressing pancreatic tumour cells, HPAF (50% lysis at
E:T 25:1), but not the autologous, mucin-expressing pancreatic
tumour cells, WM (2% lysis at E:T 25:1). It is not known whether
the non-reactivity of autologous LAK cells to its target is a specific
response to the present system or a general phenomenon.
Heterologous LAK cells (RC-LAK cells) established from
peripheral blood mononuclear cells of a pancreatic adenocarci-
noma patient, on the other hand, lysed WM cells (27% at E:T 25:1)
as well as HPAF (54% lysis at E:T 25:1) tumour cells. As
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Figure 2 Expression of MHC-Class I and Class II molecules on pancreatic tumour cell lines. The cultured tumour cells (WM and HPAF) were stained with
isotype control antibody (IgG2a), and antibodies against MHC-Class I (W6/32) and MHC-Class II (L243) followed by fluorescein-conjugated goat anti-mouse
antibodies for flow cytometry analysisexpected, both WM- and RC-LAK cells lysed the NK cell target,
K-562 (50% and 70% respectively). The results suggest that
PBMC-derived LAK cells from cancer patients did not lyse
pancreatic tumour cells in the context of mucin.
Purified pancreatic tumour cell-mucin does not elicit
mucin- or tumour cell-specific T-cell response
Previous investigators (Barnd et al, 1989) observed that purified
pancreatic tumour mucin directly stimulated T-cells established
against mucin-expressing heterologous pancreatic tumour cells. To
determine whether mucin could elicit a tumour-specific T-cell
response, purified mucin from the same source used by Barnd et al
(1989) was obtained and tested as described in Materials and
Methods. All cells could be cultured with purified mucin and IL-2
for about 2–3 months without much expansion. As shown in Table
7, the established cytotoxic T-cell line (TP) from lymph node of a
patient against irradiated T3M4 in the presence of 5 U ml–1 IL-2,
effectively lysed the stimulator cells T3M4 (78% lysis at
effector:target ratio of 25:1) and at very low levels the K-562 cells
(4.91% lysis). When these T-cells were cultured with 1900 U ml–1
mucin and 5 U ml–1 IL-2 for 5 weeks, they insignificantly killed
T-cells lack atypical recognition of mucin 697
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Table 4 Autologous but not heterologous mucinous pancreatic tumour cells enhance the stimulatory effect of IL-2 on tumour-infiltrating T-cell line and tumour-
specific peripheral blood T-cell linea
Proliferative Index
Responder Stimulator Expt. 1 Expt. 2 Expt. 3
A.
1. WM-TILs None 1.00 1.00 1.00
2. None Irr. WM-Tr. cells 0.71 ± 0.07 NT 1.16 ± 0.14
3. None Irr. HPAF 0.73 ± 0.09 NT NT
4. WM-TILs Irr. WM-Tr. cells 1.35 ± 0.08 0.72 ± 0.02 1.14 ± 0.11
5. WM-TILs Irr. HPAF 0.90 ± 0.14 0.63 ± 0.02 NT
6. WM-TILs IL-2 18.59 ± 1.90 11.83 ± 0.52 33.89 ± 1.89
7. WM-TILs Irr. WM-Tr. cells + IL-2 26.39 ± 1.19b 17.84 ± 0.24c 42.34 ± 1.26d
8. WM-TILs Irr. HPAF + IL-2 18.40 ± 1.00 12.34 ± 0.67 NT
B.
1. PBL-T cells None 1.00 1.00
2. None Irr. WM-Tr. cells 0.91 ± 0.08 0.82 ± 0.02
3. None Irr. HPAF 0.72 ± 0.01 0.93 ± 0.01
4. PBL-T cells Irr. WM-Tr. cells 1.21 ± 0.04 1.13 ± 0.01
5. PBL-T cells Irr. HPAF 1.43 ± 0.04 2.24 ± 0.34
6. PBL-T cells IL-2 13.42 ± 0.62 17.62 ± 0.48
7. PBL-T cells Irr. WM-Tr. cells + IL-2 27.22 ± 0.86e 30.20 ± 1.81f
8. PBL-T cells Irr. HPAF + IL-2 12.84 ± 0.58 18.30 ± 1.16
aWM tumour-infiltrating lymphocyte (TIL) line and tumour-specific T-cell line were established by repeatedly stimulating with autologous irradiated (Irr.) mucin-
expressing pancreatic tumour (tr.) cells (WM-tumour cells) and 5 U ml–1 interleukin-2 (IL-2). The proliferative response ([3H]thymidine incorporation) of resting
tumour-infiltrating lymphocyte line was determined in triplicates following three day incubation with mucin-expressing autologous (WM) or heterologous (HPAF)
pancreatic tumour cells in the presence or absence of 1 U ml–1 IL-2. b–fSignificantly different from respective TILs or PBL-T-cells incubated with IL-2, bP < 0.05;
cP < 0.005; dP < 0.05; eP < 0.001; fP < 0.01. NT, not tested.
Table 5 Specific stimulatory effect of autologous tumour cells and IL-2 on tumour-infiltrating T-cell linea
Proliferative index
Responder Stimulator Expt. 1 Expt. 2
1. WM-TILs None 1.00 1.00
2. None Irr. WM-tumour cells 0.83 ± 0.10 0.61 ± 0.07
3. WM-TILs Irr. WM-tumour cells 0.91 ± 0.05 1.02 ± 0.08
4. WM-TILs IL-2 + Control Ab 10.78 ± 0.62 19.22 ± 0.52
5. WM-TILs IL-2 + L243 Ab 9.70 ± 1.06 17.63 ± 0.52
6. WM-TILs Irr. WM-tumour cells + IL-2 + Control Ab 20.21 ± 1.67 31.32 ± 1.95
7. WM-TILs Irr. WM-tumour cells + IL-2 + L243 Ab 13.51 ± 0.63b 23.42 ± 0.62c
8. WM-TILs Irr. Autologous EBV-B Cells + IL-2 12.20 ± 0.72 20.32 ± 0.80
9. WM-TILs IL-2 + SP-1 Sup 11.23 ± 0.49 18.91 ± 0.95
10. WM-TILs IL-2 + DU-PAN-2 Ab 10.73 ± 0.95 18.63 ± 1.11
11. WM-TILs Irr. WM-tumour cells + IL-2 + SP-1 Sup 22.39 ± 2.34 33.52 ± 2.12
12. WM-TILs Irr. WM-tumour cells + IL-2 + DU-PAN-2 Ab 23.52 ± 1.55 32.84 ± 1.74
aWM tumour-infiltrating lymphocyte (TIL) line was established by repeatedly stimulating with autologous irradiated (Irr.) mucin-expressing pancreatic tumour
cells (WM-tumour cells) and 5 U ml–1 interleukin-2 (IL-2). The proliferative response ([3H]-thymidine incorporation) of resting tumour-infiltrating lymphocyte line
was determined in triplicates following 3-day incubation with mucin-expressing autologous (WM) pancreatic tumour cells (passage 1) in the presence or
absence of 1 U ml–1 IL-2. For blocking experiments, irradiated tumour cells were preincubated with 20 mg ml–1 control IgG2a, SP-1 supernatant (Sup), L243
(IgG2a) or DU-PAN-2 (IgM) antibody (Ab) for 60 min at 37°C and were washed in RPMI medium before adding to the responder T-cells. bStatistically not
significant from TILs incubated with irradiated WM-tumour cells, IL-2 and control antibody; cSignificantly different from TILs incubated with irradiated WM-tumour
cells, IL-2 and control antibody (P < 0.05).698 RS Selvan et al
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Table 6 Lymphokine-activated killer (LAK) cells do not recognize pancreatic tumour cells in the context of mucin
% Cytotoxicity
Effector cellsa Target tumour cells Expt. 1 Expt. 2
1. WM-LAK cells WM (autologous, mucinous) 2.07 ± 1.19 –0.91 ± 0.29
HPAF (heterologous, mucinous) 49.49 ± 2.84 25.79 ± 0.54
K-562 (LAK-cell target, non-mucinous) 50.83 ± 0.54 25.86 ± 1.35
2. RC-LAK cells WM (heterologous, mucinous) 26.98 ± 0.51 14.00 ± 1.73
HPAF (heterologous, mucinous) 54.98 ± 1.42 53.05 ± 2.41
K-562 (LAK-cell target, non-mucinous) 70.68 ± 2.69 61.36 ± 1.78
aEffector LAK cells (WM and RC) were obtained by culturing peripheral blood mononuclear cells from mucin-expressing pancreatic adenocarcinoma patients
with 1000 U ml–1 of human recombinant interleukin-2 for 5 days and the cytolytic activity was determined using various effector (E) to target (T) ratios.
The values represent percentage specific lysis obtained at E:T 25:1 in a 4 h Chromium-51 release assay. HLA pattern of effector and target cells are
given in Table 2
Table 7 Lack of mucin-specific cytotoxic response of pancreatic cancer patients’ heterologous
tumour-specific T-cell or PBMCs cultured with mucin plus IL-2
Responder Stimulus Targets % Cytotoxicityd
A. TP-T-cellsa Irr. T3M4 + IL-2 T3M4 78.17 ± 0.08
K-562 4.91 ± 0.84
TP-T cells Mucin + IL-2 T3M4 5.75 ± 0.38
generated K-562 4.17 ± 0.19
against T3M4b
B. PBMCsc IL-2 HPAF 1.38 ± 0.25
PANC-1 8.62 ± 1.20
K-562 7.79 ± 0.63
Mucin + IL-2 HPAF 1.03 ± 0.38
PANC-1 10.27 ± 0.34
K-562 11.04 ± 0.08
aTP-T-cells were established from tumour-draining lymph nodes of a pancreatic adenocarcinoma
patient against heterologous pancreatic tumour cells T3M4 by repeated stimulation with irradiated
tumour cells in the presence of 5 U ml–1 interleukin-2 for 2 months. bT3M4-specific heterologous
cytotoxic T-cells were repeatedly cultured with 1900 U ml–1 mucin and 5 U ml–1 IL-2 for 5 weeks.
cPeripheral blood mononuclear cells (PBMCs) from a cancer patient were repeatedly cultured with
5 U ml–1 IL-2 or 1900 U ml–1 mucin plus 5 U ml–1 IL-2 for 5 weeks. The data represent the cytolytic
activity of T-cell lines assessed after continuous culture against Chromium-51-labelled tumour cell
targets using various effector (E) to target (T) ratios. dValues represent percentage specific lysis
obtained at E:T 25:1 in a 4 h Chromium-51 release assay. Each experiment was repeated three
times, and data from one representative experiment are shown.
Table 8 Lack of stimulatory effect of mucin on pancreatic cancer patient’s PBMCs
Experimental Proliferative index
groups Expt. 1 Expt. 2
1. PBMCs 1.00 1.00
2. PBMCs + IL-2 (5 U ml–1) 37.13 ± 0.88 24.38 ± 0.94
3. PBMCs + Mucin (475 U ml–1) 0.56 ± 0.09 0.62 ± 0.01
4. PBMCs + Mucin (950 U ml–1) 0.37 ± 0.03 0.59 ± 0.07
5. PBMCs + Mucin (1900 U ml–1) 0.46 ± 0.13 0.54 ± 0.11
6. PBMCs + Mucin (2375 U ml–1) 0.49 ± 0.07 0.57 ± 0.05
7. PBMCs + IL-2 (5 U ml–1) + Mucin (475 U ml–1) 34.45 ± 0.29 23.45 ± 0.61
8. PBMCs + IL-2 (5 U ml–1) + Mucin (950 U ml–1) 34.80 ± 0.60 23.12 ± 0.86
9. PBMCs + IL-2 (5 U ml–1) + Mucin (1900 U ml–1) 31.77 ± 1.59a 21.67 ± 1.35b
10. PBMCs + IL-2 (5 U ml–1) + Mucin (2375 U ml–1) 28.93 ± 1.12c 19.57 ± 1.14d
The proliferative response ([3H]-thymidine incorporation) of PBMCs from cancer patients was determined following 3-day incubation in triplicates with 5 U ml–1
IL-2 or varying concentrations (475 U ml–1 to 2375 U ml–1) of mucin in the presence or absence of 5 U ml–1 IL-2. a,c,dSignificantly different from PBMCs incubated
with IL-2, aP < 0.05; bNot significant; cP < 0.01; dP < 0.05.the initial stimulator T3M4. Similarly, PANC-1-reactive CTLs,
after culturing repeatedly with mucin plus IL-2 for 5 weeks,
displayed an unresponsiveness to PANC-1 cells (data not shown).
PBMCs derived from a cancer patient, cultured either with 
5U  m l –1 IL-2 or 1900 U ml–1 mucin plus 5 U ml–1 IL-2, exhibited
low level killing of non-mucinous PANC-1 cells and NK cell
target, K-562 cells, with negligible cytotoxicity against mucinous
HPAF cells (Table 7). Culturing fresh PBMCs from cancer patients
for 3 days with varying concentration of mucin in the presence of
5U  m l –1 IL-2, did not stimulate a proliferative response over IL-2
alone (Table 8). Rather, 1900 and 2375 U ml–1 concentrations of
mucin decreased the proliferative response induced by IL-2
(11–14% and 20–22% decrease respectively; P < 0.05). The
results of these experiments reveal that the purified mucin,
(a) rendered the heterologous pancreatic tumour cell-reactive
T-cells unresponsive to its target even in the presence of IL-2, and
(b) did not produce mucin- or tumour-reactive T-cells from
patients’ peripheral blood cells even in the presence of antigen-
presenting cells and IL-2. These results fail to support the
contention that mucin is an antigen recognized by T-cells from
cancer patients.
DISCUSSION
Barnd et al (1989) claimed a general MHC-unrestricted recogni-
tion of mucin by heterologous T-cells based on one patient. Since
an autologous cell system was not available, Barnd et al (1989)
used a heterologous cell system. The results of our investigation
do not support MHC-unrestricted recognition of pancreatic tumour
mucin by pancreatic tumour cell-reactive heterologous cytotoxic
T-cells. WM-cytotoxic T-cells established against heterologous
tumour cells HPAF lysed the stimulating target cells HPAF as well
as mucin-non-expressing PBL-blast cells that possessed matching
MHC class I alleles with the stimulator (HPAF). These T-cells,
however, did not lyse autologous tumour cells in spite of
expressing mucin on the surface, further indicating an allogeneic
response. Furthermore, the autologous T-cells, proliferated against
their own tumour cell target WM, did not respond to heterologous,
mucinous-tumour cell line HPAF, thus revealing no MHC-
unrestricted recognition of mucin. Even, PBMC-derived LAK
cells did not universally recognize pancreatic tumour cells that
expressed mucin. If mucin were recognized, LAK cells would
have killed the autologous pancreatic tumour cells that expressed
mucin. In another paper, Jerome et al (1991) reported that lymph
node cells obtained from two patients were alternatively stimu-
lated by varying the stimulator cells (lymph node cells from each
patient were stimulated with five different heterologous, HLA-
unmatched tumour cells in an alternating fashion). It is unclear
what kinds of T-cells were generated in such a situation. Although
these investigators justified the use of such a method of
stimulation, their observation does not unequivocally disregard the
presence of alloreactivity. If one were to agree that such method-
ology is appropriate, it should have been employed in other studies
as well. That does not seem to be the case (Barnd et al, 1989;
Margarian-Blander et al, 1998).
In the present study, we did not observe a promiscuous reac-
tivity of heterologous T-cells against a variety of mucin-expressing
pancreatic and breast tumour cell lines. An initial study by Barnd
et al (1989) on heterologous pancreatic tumour cell-reactive
T-cells did not provide information regarding the similarities and
the differences in HLA class I molecules of cells used in their
experiments. Although, in a later study (Jerome et al, 1991),
HLA-defined breast and pancreatic tumour cell-reactive T-cells
were used in some cases, the complexity involved in the stimula-
tion of lymph node cells with varying heterologous tumour cells
by rotation precludes observation of the hidden MHC-restricted
recognition. The potential alloreactivity in the heterologous
tumour cell-reactive T-cell system might have contributed to the
cellular immune response which the previous investigators
attributed solely to MUC-1 reactivity (Barnd et al, 1989; Jerome
et al, 1991; Magarian-Blander et al, 1998). Notably, one of the
synthetic nine-amino acid long peptides designed from the section
of the tandem repeats of mucin was shown to bind HLA-A11 and
to generate peptide-specific CTLs from PBLs of several healthy
HLA-A11 donors (Domenech et al, 1995). The characteristics of
this HLA-restricted epitope in the T-cell response to autologous,
and/or heterologous, mucin-expressing pancreatic tumour cells
were not determined. Subsequent indirect studies which extended
the atypical recognition of mucin by tumour cell-reactive heterolo-
gous T-cells are inconclusive (Domenech et al, 1995; Henderson et
al, 1996; Magarian-Blander et al, 1996, 1998; Bohm et al, 1997;
Goydos et al, 1997). Mucin has yet to be demonstrated as an
antigen recognized by pancreatic tumour cell-reactive autologous
T-cells.
Consistent with the present findings, other investigators (Katano
et al, 1993; Wolfel et al, 1993; Peiper et al, 1997a) established
pancreatic tumour-reactive autologous T-cell systems and demon-
strated that CTLs indeed lysed autologous tumour cells in an HLA
class I-restricted fashion. No significant cytotoxicity was found
against autologous fibroblasts, several heterologous pancreatic
cancer cell lines or an NK cell target, K-562 cells. Subsequently,
Peiper et al (1997b) demonstrated that autologous pancreatic
tumour-reactive CTLs recognized HER2/neu, a transmembrane
protein with extensive homology to the epidermal growth factor
receptor. These CTLs from pancreatic tumour-associated lympho-
cytes were shown to recognize autologous and heterologous
HER2/neu+ tumour cells in an HLA-A2-restricted fashion. In an
indirect approach, other investigators detected primed MHC-
restricted T-cell immunity to p21ras protein and/or peptides in
some patient with pancreatic and colon cancer (Qin et al, 1995;
Gjertsen et al, 1996). In the present work, autologous pancreatic
tumour cell-reactive CD4+ T-cells but not CD8+ T-cells were
generated from tumour-infiltrating and peripheral blood lympho-
cytes. Of note, during an initial expansion of autologous tumour
cell-reactive T-cells from peripheral blood mononuclear cells,
cytotoxic CD8+ T-cells were seen (RS Selvan, unpublished obser-
vation). After a few rounds of stimulation with irradiated autolo-
gous tumour cells and IL-2, only non-cytotoxic CD4+ T-cells were
expanded. The functional role of such T-cells is currently
unknown. In a melanoma system, investigators have demonstrated
that autologous melanoma-reactive CD4+ T cells possessed
suppressor function against cytotoxic T-cell function (Chakraborty
et al, 1990). The existence of suppressor T-cell function attribut-
able to our autologous pancreatic tumour-reactive CD4+ T-cells
remains to be determined.
The results of the present study also raise the question whether
mucin is significantly immunogenic. We did not observe stimula-
tory effects of purified tumour-mucin and IL-2 on established,
heterologous pancreatic tumour cell-reactive T-cells. This suggests
that (a) purified mucin does not replace the stimulating mucinous-
tumour cells, and (b) the lack of periodic stimulation diminishes
the reactivity of established T-cells against the stimulating target
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tumour cell-reactive T-cells from patients’ PBMCs with purified
mucin and IL-2, even in the presence of antigen-presenting cells.
Our results suggest that in our autologous system, mucin is more
likely not the recognition antigen. If it were the antigen, we would
have generated mucin or tumour-specific T-cell response from
PBMCs, lymph node cells or splenic cells of mucinous-tumour
patients, cultured with purified mucin and IL-2. We did not detect
such a response in our cultures. We cannot rule out the possibility
that tumour-reactive autologous T-cells might still be recognizing
unique determinant(s) of mucin on tumour cells. In order to estab-
lish whether mucin on tumour cells is recognized by T cells,
unique determinants need to be identified using a direct approach,
such as gene transfection with cDNA library of mucinous tumour
cells, and subsequent screening of transfectants with tumour
cell-reactive autologous T-cell clone (Deplean et al, 1997).
Interestingly, previous investigators (Barnd et al, 1989) observed
that purified tumour-mucin directly stimulated the T-cells that
were established against mucin-expressing heterologous pancre-
atic tumour cells. Further investigations explored the role of mucin
as a possible tumour vaccine (Goydos et al, 1997). A recent study
(McKolanis et al, 1996) noted that mucin-specific T-cells are very
rare in tumour draining lymph nodes. MUC-1 has also been shown
not to induce apoptosis in T-cells but to inhibit human T-cell
proliferative responses (Agrawal et al, 1998; Boussiotis et al,
1998). In addition, a previous study (Agrawal et al, 1998) demon-
strated that polyclonal proliferative response of T-cells was
restored when IL-2 was included with purified mucin. Contrary to
this observation, Paul et al (1999) found no evidence for an
inhibitory role for MUC-1. Furthermore, in sharp contrast to the
present study, previous investigators (Wahab and Metzgar, 1991)
noted that T-cells were inhibited by HPAF cells which expressed
high levels of mucin. This observation questions the immuno-
genicity of pancreatic tumour mucin, MUC-1.
Investigations on autologous pancreatic tumour cell-reactive
T cells as well as HLA-defined heterologous pancreatic tumour
cell-reactive T-cells underscore the importance of establishing
several pancreatic tumour cell-reactive, autologous T-cell systems
in vitro for use in the identification of novel tumour-associated
antigens. For example, the identification of immunological and
genetic reagents displaying the appropriate specificity will help in
distinguishing between pancreatic adenocarcinoma and normal
pancreas (Grem, 1997). A large number of studies have identified
several novel tumour-associated antigens using autologous T-cells
in other solid malignancies such as melanoma (Robbins and
Kawakami, 1996). Ultimately, there is a need for systematic iden-
tification and characterization of pancreatic tumour-associated
antigens. The immune responses directed against them will
advance our understanding of pancreatic tumour-specific immu-
nity and facilitate the developments of novel therapeutics, possibly
including tumour vaccines.
ACKNOWLEDGEMENTS
Special thanks to Dr Richard S Metzgar (Emeritus Professor) for
his interest, encouragement and support with this work. Thanks to
Kathryn M Roberson for her advice with primary culture of
tumour cells; Michael S Lan (currently at the Department of
Pediatrics, Lousiana State University, New Orleans, LA) for puri-
fied pancreatic tumour mucin; Frank L Tuck for assistance with
immunocytochemistry; Angelica DeOliveria for devoting her time
in HLA typing of tumour cells and peripheral blood lymphocytes;
and Michael J Cook for flow cytometry analysis. George Padilla,
Mepur Ravindranath, Rob Stephenson, Penny Miron and Scott
Pruitt are gratefully acknowledged for critical comments on the
manuscript. Clinical samples used in this work were obtained in
accordance with the institutional review board (IRB) protocols and
patient’s consent.
REFERENCES
Agrawal B, Krantz MJ, Reddish MA and Longenecker B (1998) Cancer-associated
MUC1 mucin inhibits human T cell proliferation, which is reversible by IL-2.
Nat Med 4: 43–49
Barnd DL, Lan MS, Metzgar RS and Finn OJ (1989) Specific, major
histocompatibility complex-unrestricted recognition of tumour-associated
mucins by cytotoxic T cells. Proc Natl Acad Sci USA 86: 7159–7163
Belldegrun A, Kasid A, Uppenkamp M, Topalian SL and Rosenberg SA (1989)
Human tumor-infiltrating lymphocytes: analysis of lymphokine mRNA
expression and relevance to cancer immunotherapy. J Immunol 142:
4520–4526
Bohm CM, Mulder MC, Zennadi R, Notter M, Schmitt-Graft A, Finn OJ, Taylor
Papadimitriou J, Stein H, Clausen H, Riecken EO and Hanski C (1997)
Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity
of a T cell subpopulation. Scand J Immunol 46: 27–34
Borowitz MJ, Tuck FL, Sindelar WF, Fernsten PD and Metzgar RS (1984)
Monoclonal antibodies against human pancreatic adenocarcinoma: distribution
of DU-PAN-2 antigen on glandular epithelia and adenocarcinoma. J Natl
Cancer Inst 72: 999–1005
Boussiotis VA, Freeman GJ, Gribben JG, Hayes DF and Nadler LM (1998) No
evidence for MUC1-induced apoptosis. Nat Med 4: 1093
Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE and
Mukherji B (1990) Autologous melanoma-induced activation of regulatory T
cells that suppress cytotoxic response. J Immunol 145: 2359–2364
De Plean E, Lurquin C, Lethe B, van der Bruggen P, Brichard V, Renauld JC, Coulie
P, Van Pel A and Boon T (1997) Identification of genes coding for tumor
antigens recognized by cytolytic T lymphocytes. Methods 12: 125–142
Domenech N, Henderson RA and Finn OJ (1995) Identification of an HLA-A11-
restricted epitope from the tandem repeat domain of the epithelial tumor
antigen mucin. J Immunol 155: 4766–4774
Gjertsen MK, Saeterdal I, Thorsby E and Gaudernack G (1996) Characterization of
immune responses in pancreatic carcinoma patients after mutant p21 ras
peptide vaccination. Br J Cancer 74: 1828–1833
Goydos JS, Elder E, Whiteside TL, Finn OJ and Lotze MT (1997) A phase I trial of
a synthetic mucin peptide vaccine. Induction of specific immune reactivity in
patients with adenocarcinoma. J Surg Res 63: 298–304
Grem J (1997) The prognostic importance of tumor markers in adenocarcinoma of
the gastrointestinal tract. Curr Opin Oncol 9: 380–387
Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA (1982) Lymphokine-
activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid
tumor cells by interleukin 2-activated autologous human peripheral blood
lymphocytes. J Exp Med 155: 1823–1841
Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PF, Ball ED and Finn OJ
(1996) Human dendritic cells genetically engineered to express high levels of
the human epithelial tumor antigen mucin (MUC-1). Cancer Res 56:
3763–3770
Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie
IFC, Bast RC Jr and Finn OJ (1991) Cytotoxic T lymphocytes derived from
patients with breast adenocarcinoma recognize an epitope present on the
protein core of a mucin molecule preferentially expressed by malignant cells.
Cancer Res 51: 2908–2916
Katano M, Nagumo F, Kubota E, Yamamoto H, Matsuo T, Hisatsugu T and Tadano J
(1993) Autologous tumor-specific cytotoxic T cell clone established from
tumor-infiltrating lymphocytes (TIL) of malignant ascites in the absence of
recombinant interleukin 2 (rIL-2): activation by autologous tumor cell alone.
Biother 6: 25–32
Lan MS, Finn OJ, Fernsten PD and Metzgar RS (1985) Isolation and properties of a
human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. Cancer Res
45: 305–310
700 RS Selvan et al
British Journal of Cancer (2000) 82(3), 691–701 © 2000 Cancer Research CampaignLan MS, Khorrami A, Kaufman B and Metzgar RS (1987) Molecular
characterization of a mucin-type antigen associated with human pancreatic
cancer. The DU-PAN-2 antigen. J Biol Chem 262: 12863–12870
McKolanis J, Pecher G, Lotze M and Finn OJ (1996) Mucin reactive CTL induced
by in vivo immunization (Abstr). Proc Am Assoc Cancer Res 87: 3144
Magarian-Blander J, Hughey RP, Kinlough C, Poland PA and Finn OJ (1996)
Differential expression of MUC1 on transfected cell lines influences its
recognition by MUC1 specific T cells. Glycoconjugate J 13: 749–756
Magarian-Blander J, Ciborowski P, Hsia S, Watkins SC and Finn OJ (1998)
Intercellular and intracellular events following the MHC-unrestricted TCR
recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1.
J Immunol 160: 3111–3120
Metzgar RS, Rodriguez N, Finn OJ, Lan MS, Daasch VN, Fernsten PD, Meyers WC,
Sindelar WF, Sandler RS and Seigler HF (1984) Detection of a pancreatic
cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients
with adenocarcinoma. Proc Natl Acad Sci USA 81: 5242–5246
Miller G and Lipman M (1973) Release of infectious Epstein–Barr virus by
transformed marmoset leukocytes. Proc Natl Prod USA 70: 190–194
Paul S, Bizouarne N, Paul A, Price MR, Hansson GC, Kieny MP and Acres RB
(1999) Lack of evidence for an immunosuppressive role for MUC1. Cancer
Immunol Immunother 48: 22–28
Peiper M, Nagoshi M, Patel D, Fletcher JA, Geogebuure PS and Eberlein TJ (1997a)
Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor-
infiltrating lymphocytes after in vitro as well as in vivo tumor expansion.
Int J Cancer 71: 993–999
Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC and Eberlein TJ
(1997b) The HER2/neu-derived peptide p654–662 is a tumor-associated
antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Eur J Immunol 27: 1115–1123
Poland PA, Kinlough CL, Rokaw MD, Magarian-Blander J, Finn OJ and Hughey RP
(1997) Differential glycosylation of MUC1 in tumors and transfected epithelial
and lymphoblastoid cell lines. Glycoconjugate J 14: 89–96
Pollack MS, Heagney SD, Livingston PO and Fogh J (1981) HLA-A, B, C and DR
alloantigen expression on forty-six cultured human tumor cell lines. J Natl
Cancer Inst 66: 1003–1012
Qin H, Chen H, Takahashi M, Disis ML, Byrd DR, McCahill L, Bertram KA, Fenton
RG, Peace DJ and Cheever MA (1995) CD4+ T cell immunity to mutated ras
protein in pancreatic and colon cancer patients. Cancer Res 55: 2984–2987
Robbins PF and Kawakami Y (1996) Human tumor antigens recognized by T cells.
Curr Opin Immunol 8: 628–636
Selvan RS, Nagarkatti PS and Nagarkatti M (1990) Role of IL-2, IL-4 and IL-6 in
the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T
cytotoxic cells. Int J Cancer 45: 1096–1104
Selvan RS, Nagarkatti PS and Nagarkatti M (1991) Characterization of T
lymphocyte clones isolated from BCNU-cured LSA mice. Int J Cell Cloning 9:
594–605
Slovin SF, Lackman RD, Ferrone S, Kiely PE and Mastrangelo MJ (1986) Cellular
immune response to human sarcomas: cytotoxic T cell clones reactive with
autologous sarcomas. I. Development, phenotype, and specificity. J Immunol
137: 3042–3048
Tan MH, Nowak NJ, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian R,
Douglass HO and Ming Chu T (1986) Characterization of a new primary
pancreatic tumor line. Cancer Invest 4: 15–23
Wahab ZA and Metzgar RS (1991) Human cytotoxic lymphocytes reactive with
pancreatic adenocarcinoma cells. Pancreas 6: 307–317
Wolfel T, Herr W, Coulie P, Schmitt U, Meyer Zum Buschenfelde K-H and Knuth A
(1993) Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class
I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer 54: 636–644.
T-cells lack atypical recognition of mucin 701
British Journal of Cancer (2000) 82(3), 691–701 © 2000 Cancer Research Campaign